• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Monopar Therapeutics Inc (NQ: MNPR )

    2.580 +0.100 (+4.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,261,296
    Open 2.350
    Bid (Size) 2.600 (1)
    Ask (Size) 2.760 (1)
    Prev. Close 2.480
    Today's Range 2.150 - 2.870
    52wk Range 0.2739 - 2.870
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
    From Monopar Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +597.30%
    +597.30%
    1 Month
    +306.30%
    +306.30%
    3 Month
    +319.79%
    +319.79%
    6 Month
    +352.63%
    +352.63%
    1 Year
    +316.13%
    +316.13%

    More News

    Read More
    MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Recap: Monopar Therapeutics Q4 Earnings
    Via Benzinga
    Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Monopar and NorthStar Amend & Extend Collaboration
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
    Via InvestorPlace
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Monopar Announces CFO Succession
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.